![](/images/graphics-bg.png)
Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
Joint Authors
Sobash, Philip T.
Kota, Vamsi
Guddati, Achuta Kumar
Source
Case Reports in Oncological Medicine
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-04-07
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Ruxolitinib has become a new therapeutic option for steroid refractory graft-versus-host disease (srGVHD), with a substantial remission rate.
Its anti-inflammatory properties by blocking interleukin pathways have made it a novel therapeutic approach to inflammatory disease processes, such as GVHD.
The long-term use of ruxolitinib has not been explicitly studied outside the context in the treatment of multiple myeloma.
With current clinical trials underway for the use of ruxolitinib in srGVHD, there are still no current guidelines or protocols for long-term clinical use.
Of the available literature showing ruxolitinib utilization for srGVHD, most cases lead to resolution and eventual discontinuation.
We present a case of a 32-year-old male on ruxolitinib with GVHD status postmatched unrelated donor stem cell transplant (MUD SCT) for acute myeloid leukemia (AML) with FLT3 mutation currently on ruxolitinib for 5 years who is not able to tolerate reduction in dosage due to flare-ups.
We discuss the clinical implications and nuance of therapy with ruxolitinib with unknown long-term effects and weigh the risks and benefits.
American Psychological Association (APA)
Sobash, Philip T.& Guddati, Achuta Kumar& Kota, Vamsi. 2020. Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD. Case Reports in Oncological Medicine،Vol. 2020, no. 2020, pp.1-3.
https://search.emarefa.net/detail/BIM-1149410
Modern Language Association (MLA)
Sobash, Philip T.…[et al.]. Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD. Case Reports in Oncological Medicine No. 2020 (2020), pp.1-3.
https://search.emarefa.net/detail/BIM-1149410
American Medical Association (AMA)
Sobash, Philip T.& Guddati, Achuta Kumar& Kota, Vamsi. Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD. Case Reports in Oncological Medicine. 2020. Vol. 2020, no. 2020, pp.1-3.
https://search.emarefa.net/detail/BIM-1149410
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1149410